NCT00142987View on ClinicalTrials.gov

Efficacy of Tegaserod in Relieving the Symptoms of Female Patients With Irritable Bowel Syndrome (IBS), Excluding Those With Predominant Diarrhea IBS

PHASE4CompletedINTERVENTIONAL
Enrollment

664

Participants

Timeline

Start Date

April 30, 2004

Study Completion Date

June 30, 2005

Conditions
IBS-C and IBS With Mixed Bowel Habits
Interventions
DRUG

Tegaserod

Sponsors

Lead Sponsor

Novartis
All Listed Sponsors
lead

Novartis

INDUSTRY

NCT00142987 - Efficacy of Tegaserod in Relieving the Symptoms of Female Patients With Irritable Bowel Syndrome (IBS), Excluding Those With Predominant Diarrhea IBS | Biotech Hunter | Biotech Hunter